<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365603">
  <stage>Registered</stage>
  <submitdate>10/01/2014</submitdate>
  <approvaldate>23/01/2014</approvaldate>
  <actrnumber>ACTRN12614000090617</actrnumber>
  <trial_identification>
    <studytitle>Confirmatory pharmacokinetic study of paracetamol and phenylephrine hydrochloride in healthy adults</studytitle>
    <scientifictitle>Comparative, randomized, single dose, three-period, cross-over open label study to evaluate the pharmacokinetic parameters of a new formulation of paracetamol and phenylephrine tablets (Maxiclear) relative to an oral administration of fixed dose combination of paracetamol 1000 mg and phenylephrine 10 mg and relative  to an oral administration of phenylephrine 10 mg tablets alone, in healthy adults under fasting conditions</scientifictitle>
    <utrn />
    <trialacronym>AFT-MXCF-02</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cold &amp; Flu</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Drug &amp; Dose: Combinations of Paracetamol 1000mg with Phenylephrine 5mg and with Phenylephrine 10 mg
Dose frequency: Single dose
Duration Administration: Single dose
Mode Administration:Oral tablet
Washout between treatments = 7 days 
Treatment arms: 3
Arm 1: Paracetamol 1000 mg and Phenylephrine 5 mg
Arm 2: Paracetamol 1000 mg and Phenylephrine 10 mg
Arm 3: Phenylephrine 10 mg
All participants complete intervention Arms 1 and 2 and control arm 3
</interventions>
    <comparator>Drug &amp; Dose: Phenylephrine 10 mg
Dose frequency: Single dose
Duration Administration: Single dose
Mode Administration:Oral tablet 
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluation of pharmacokinetic paramaters [Cmax, AUC, Tmax, T 1/2] of Phenylephrine hydrochloride
Assessed by measurement of plasma drug concentrations
</outcome>
      <timepoint>Single dose study measuring plasma concentrations over 5, 15, 30, 45 minutes and 1, 1.25, 1.5, 2, 3, 6, 8, 10 and 12 hours after study drug administration </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety will be evaluated during each study period, and for 7 days following study drug administration. 
An acute safety evaluation will be performed during each study period by recording spontaneously reported adverse events and by clinical assessments, including measurements of blood pressure and heart rate.

Known phenylephrine hydrochloride adverse effects (i.e increased systolic and diastolic blood pressure, palpitations, headache, vomiting, nervousness), and known paracetamol adverse effects (i.e. clinical evidence of hepatotoxicity) will be compared between groups.
Adverse events will continue to be assessed up to 7 days after the last dose of the study medication by spontaneous reporting and at a final follow-up phone call.
</outcome>
      <timepoint>Single dose study measuring plasma concentrations over 5, 15, 30, 45 minutes and 1, 1.25, 1.5, 2, 3, 6, 8, 10 and 12 hours after study drug administration
Safety will be evaluated during each study period, and for 7 days following study drug administration. 
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>pregnancy, nursing, drug abuse, smoking &gt; 10 cigarettes per day, excess alcohol intake, prescription drugs within 14 days of the study, participating in another trial within 80 days, clinically significant abnormal lab tests </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>3/02/2014</anticipatedstartdate>
    <actualstartdate>14/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>22/04/2014</actualenddate>
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AFT Pharmaceuticals Ltd</primarysponsorname>
    <primarysponsoraddress>Level 1, 129 Hurstmere Rd, Takapuna, Auckland, 0622, New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AFT Pharmaceuticals Ltd</fundingname>
      <fundingaddress>Level 1, 129 Hurstmere Rd, Takapuna, Auckland, 0622, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress>none</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To measure the pharmacokinetics [how the body treats drugs] of phenylephrine in humans since this is still not well understood and to check this specifically for a tablet mixture of paracetamol and phenylephrine called Maxiclear. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IPRC Institutional Review Board</ethicname>
      <ethicaddress>172 Queen Rania St
PO Box 963166
Amman 11942
</ethicaddress>
      <ethicapprovaldate>13/03/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>20/01/2014</ethicsubmitdate>
      <ethiccountry>Jordan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr.Naji Najib</name>
      <address>International Pharmaceutical Research Center Queen Rania St - Sport City Circle PO Box 963166 Amman 11196 </address>
      <phone>+962562764/51</phone>
      <fax>+96265627654</fax>
      <email>iprc@iprc.com.jo</email>
      <country>Jordan</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hartley Atkinson</name>
      <address>AFT Pharmaceuticals Ltd, Level 1, 129 Hurstmere Rd, Takapuna, Auckland 0622 </address>
      <phone>+6494880232</phone>
      <fax>+6494880234 </fax>
      <email>hartley@aftpharm.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hartley Atkinson</name>
      <address>AFT Pharmaceuticals Ltd, Level 1, 129 Hurstmere Rd, Takapuna, Auckland 0622 </address>
      <phone>+6494880232</phone>
      <fax>+6494880234 </fax>
      <email>hartley@aftpharm.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>